• Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process

  • Sep 19 2024
  • Length: 35 mins
  • Podcast

Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process

Listen for free

View show details

  • Summary

  • Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through the downmarket. His strategy, to own clinical trials and manufacturing early on, looks particularly prescient in light of the cost and supply constraints threatening many biotechs today. On this episode of The BioCentury Show, Editor in Chief Simone Fishburn sits down with Oyler to discuss the early strategies that are now paying off for the global oncology company.

    View full story: https://www.biocentury.com/article/653597

    #biotech #biopharma #pharma #lifescience #drugdevelopment

    00:00 - Introduction
    11:20 – In-house Manufacturing
    15:51 – BeiGene’s Pipeline
    23:45 – Partnering Plans
    27:00 – Building a High Value Biotech
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available